9:47 a.m., EST
ZeroHedge Report Acts Like It’s Not Here
Jerimiah Babe says “Have You Looked Outside?”
If the mainstream media is good for anything, it’s the ability to keep the herd, the retail, (Robinhood kids, et al.) fully distracted until it’s absolutely too late for action.
Even though this report from ZeroHedge gives all kinds of ‘signals’ saying we’re not there yet; It even goes as far as showing there’s no yield curve inversion. Of course that means ‘no risk’ of bear market.
Then going on to say, ‘None of these measures indicate a bear market is near’. I mean, you can’t make this stuff up.
What’s the table above (yesterday’s close) say about what’s really going on?
At this point it’s obvious the media are not going to discuss the on-going bear market in biotech, SPBIO.
Doing so, would require some kind of investigation as to why? That would open Pandora’s box and have everyone digging for truth … something to be avoided (censured) at all costs.
Amateurs always want (need) to know why.
Livermore was never concerned with the why. He looked for ‘what’. What is the price action doing now or what is it likely to do.
As Wyckoff said, ‘the why always comes out later … after the fact’
‘Why’ is a useless trading strategy.
However, in the case of biotech, we can take a good guess what the ‘why’ is all about.
Fall and Winter are very close now. As this interview with Stew Peters reveals, Fall and Winter are when we get the real picture of ‘side effects’.
Biotech is ahead of the pack on the downside and for good reason.
Positions have not changed except for additions of LABD as SPBIO declines and LABD heads higher (not advice, not a recommendation).
As a reminder, this site’s not interested in day trading or even swing trading unless that’s all the market offers.
No, we’re interested in positioning strategically.
This type of trading is modeled after the host’s twenty-four years of experience with aircraft flight test and certification.
A typical project would take five to seven years to complete; have a near infinite number of complex stages along the way with each one a profession unto itself.
At this juncture, biotech may be poised for the largest implosion ever seen in market history.